September 27, 2018Press Releases
AUSTIN, Texas & CAMBRIDGE, Mass. & FARGO, N.D.–(BUSINESS WIRE)–Sep. 27, 2018– Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, has signed an agreement with Aldevron, a leading contract manufacturing organization, to supply TUSC2 (Tumor Suppressor Candidate2) plasmid DNA for use in Genprex’s clinical development program evaluating its […]